TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: tDCS in Chronic Stroke Recovery-pilot
Brief Summary: The hypothesis of this study is that different subgroups of stroke will respond differently to direct current stimulation.


Options:
A: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Implicit Learning Approach; Type: EXPERIMENTAL; Interventions: Other: Implicit Learning Approach | Intervention Type: OTHER; Name: Implicit Learning Approach; Assigned to Arm(s): Implicit Learning Approach
B: Intervention Type: OTHER; Name: Visumotor Upper Extremity Training; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: Anodal/Sham tDCS; Assigned to Arm(s): N/A
C: Arm Label: subcortical; Type: EXPERIMENTAL; Interventions: Device: tDCS | Arm Label: cortical; Type: EXPERIMENTAL; Interventions: Device: tDCS | Intervention Type: DEVICE; Name: tDCS; Assigned to Arm(s): cortical, subcortical
D: Arm Label: Early Locomotor Training Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early locomotor training program | Arm Label: Late Locomotor Training Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Late locomotor training program | Arm Label: Early Home Exercise Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home Exercise Program | Intervention Type: BEHAVIORAL; Name: Early locomotor training program; Assigned to Arm(s): Early Locomotor Training Program | Intervention Type: BEHAVIORAL; Name: Late locomotor training program; Assigned to Arm(s): Late Locomotor Training Program | Intervention Type: BEHAVIORAL; Name: Home Exercise Program; Assigned to Arm(s): Early Home Exercise Program

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: tDCS in Chronic Stroke Recovery-pilot
Brief Summary: The hypothesis of this study is that different subgroups of stroke will respond differently to direct current stimulation.


Options:
A: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: HEP-OKS; Type: EXPERIMENTAL; Interventions: Behavioral: hemifield eye patching (HEP) + optokinetic stimulation (OKS) | Intervention Type: BEHAVIORAL; Name: hemifield eye patching (HEP) + optokinetic stimulation (OKS); Assigned to Arm(s): HEP-OKS
B: Arm Label: real-tDCS with MI-BCI; Type: ACTIVE_COMPARATOR; Interventions: Device: real-tDCS with MI-BCI | Arm Label: sham-tDCS with MI-BCI; Type: SHAM_COMPARATOR; Interventions: Device: real-tDCS with MI-BCI | Intervention Type: DEVICE; Name: real-tDCS with MI-BCI; Assigned to Arm(s): real-tDCS with MI-BCI, sham-tDCS with MI-BCI
C: Arm Label: Anodal tDCS; Type: EXPERIMENTAL; Interventions: Device: Anodal transcranial direct current stimulation | Arm Label: Cathodal tDCS; Type: EXPERIMENTAL; Interventions: Device: Cathodal transcranial direct current stimulation | Arm Label: Bilateral tDCS; Type: EXPERIMENTAL; Interventions: Device: Bilateral transcranial direct current stimulation | Arm Label: Sham tDCS; Type: SHAM_COMPARATOR; Interventions: Device: Sham transcranial direct current stimulation | Intervention Type: DEVICE; Name: Anodal transcranial direct current stimulation; Assigned to Arm(s): Anodal tDCS | Intervention Type: DEVICE; Name: Cathodal transcranial direct current stimulation; Assigned to Arm(s): Cathodal tDCS | Intervention Type: DEVICE; Name: Bilateral transcranial direct current stimulation; Assigned to Arm(s): Bilateral tDCS | Intervention Type: DEVICE; Name: Sham transcranial direct current stimulation; Assigned to Arm(s): Sham tDCS
D: Arm Label: subcortical; Type: EXPERIMENTAL; Interventions: Device: tDCS | Arm Label: cortical; Type: EXPERIMENTAL; Interventions: Device: tDCS | Intervention Type: DEVICE; Name: tDCS; Assigned to Arm(s): cortical, subcortical

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Postoperative Pain After Pediatric Umbilical Hernia Repair: a Randomized Clinical Trial of Ultrasound-guided Bilateral Rectus Sheath Blocks Versus Local Anesthetic Infiltration
Brief Summary: The purpose of this study is to compare the use of ultrasound-guided bilateral rectus sheath blocks to local infiltration of anesthetic agent in the surgical wound in a pediatric population of patients undergoing umbilical hernia repair.


Options:
A: Arm Label: Transversus Abdominis Plane Block; Type: EXPERIMENTAL; Interventions: Procedure: Transversus Abdominis Plane Block | Arm Label: Caudal Epidural Block; Type: EXPERIMENTAL; Interventions: Procedure: Caudal Epidural | Intervention Type: PROCEDURE; Name: Caudal Epidural; Assigned to Arm(s): Caudal Epidural Block | Intervention Type: PROCEDURE; Name: Transversus Abdominis Plane Block; Assigned to Arm(s): Transversus Abdominis Plane Block
B: Arm Label: Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levobupivacaine, Drug: Saline | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Levobupivacaine, Drug: Saline | Intervention Type: DRUG; Name: Levobupivacaine; Assigned to Arm(s): Control group, Treatment | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Control group, Treatment
C: Arm Label: Regional block; Type: EXPERIMENTAL; Interventions: Procedure: bilateral ultrasound-guided rectus sheath block | Arm Label: Wound infiltration; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Wound infiltration | Intervention Type: PROCEDURE; Name: bilateral ultrasound-guided rectus sheath block; Assigned to Arm(s): Regional block | Intervention Type: PROCEDURE; Name: Wound infiltration; Assigned to Arm(s): Wound infiltration
D: Arm Label: Quadratus Lumborum Block; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Quadratus Lumborum Block | Arm Label: Transversus abdominis plane block; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transversus Abdominis Plane Block | Intervention Type: PROCEDURE; Name: Quadratus Lumborum Block; Assigned to Arm(s): Quadratus Lumborum Block | Intervention Type: PROCEDURE; Name: Transversus Abdominis Plane Block; Assigned to Arm(s): Transversus abdominis plane block

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Troponin Elevation in Consecutive Patients With Hip Fracture
Brief Summary: The aims of this study is to study the occurrence of the troponin elevations, ECG changes, and cardiac symptoms in unselected consecutive patients with hip fracture.

Followup will be carried out up to one year period.


Options:
A: N/A
B: N/A
C: N/A
D: Arm Label: patients with hip fracture; Type: N/A; Interventions: Other: observation | Intervention Type: OTHER; Name: observation; Assigned to Arm(s): patients with hip fracture

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomised, Double-blind Phase III Trial to Investigate the Efficacy and Safety of BIBF 1120 in Combination With Carboplatin and Paclitaxel Compared to Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
Brief Summary: The trial will be performed to evaluate if BIBF 1120 in combination with paclitaxel and carboplatin is more effective than placebo in combination with paclitaxel and carboplatin in first-line treatment of patients with advanced ovarian cancer. Safety information about BIBF1120/paclitaxel/carboplatin will be obtained.


Options:
A: Arm Label: Aflibercept 2.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Arm Label: Aflibercept 4.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept 4.0 mg/kg | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept 2.0 mg/kg
B: Arm Label: Carboplatin and gemcitabine + bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Gemcitabine, Drug: Bevacizumab | Arm Label: Carboplatin and gemcitabine + placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Gemcitabine, Drug: Placebo | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Carboplatin and gemcitabine + bevacizumab, Carboplatin and gemcitabine + placebo | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Carboplatin and gemcitabine + bevacizumab, Carboplatin and gemcitabine + placebo | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Carboplatin and gemcitabine + bevacizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Carboplatin and gemcitabine + placebo
C: Arm Label: SPARC-08-038; Type: EXPERIMENTAL; Interventions: Drug: SPARC-08-038, Drug: Ref-08-038 | Arm Label: Ref-08-038; Type: ACTIVE_COMPARATOR; Interventions: Drug: SPARC-08-038, Drug: Ref-08-038 | Intervention Type: DRUG; Name: SPARC-08-038; Assigned to Arm(s): Ref-08-038, SPARC-08-038 | Intervention Type: DRUG; Name: Ref-08-038; Assigned to Arm(s): Ref-08-038, SPARC-08-038
D: Arm Label: BIBF 1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120, Drug: Paclitaxel, Drug: Carboplatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): BIBF 1120 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): BIBF 1120 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): BIBF 1120

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomised, Double-blind Phase III Trial to Investigate the Efficacy and Safety of BIBF 1120 in Combination With Carboplatin and Paclitaxel Compared to Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
Brief Summary: The trial will be performed to evaluate if BIBF 1120 in combination with paclitaxel and carboplatin is more effective than placebo in combination with paclitaxel and carboplatin in first-line treatment of patients with advanced ovarian cancer. Safety information about BIBF1120/paclitaxel/carboplatin will be obtained.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1
B: Arm Label: Rucaparib; Type: EXPERIMENTAL; Interventions: Drug: Rucaparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rucaparib; Assigned to Arm(s): Rucaparib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: BIBF 1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120, Drug: Paclitaxel, Drug: Carboplatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): BIBF 1120 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): BIBF 1120 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): BIBF 1120
D: Arm Label: Phase Ib/II: Fosbretabulin & Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Fosbretabulin | Arm Label: Phase II: Pazopanib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Phase II: Pazopanib, Phase Ib/II: Fosbretabulin & Pazopanib | Intervention Type: DRUG; Name: Fosbretabulin; Assigned to Arm(s): Phase Ib/II: Fosbretabulin & Pazopanib

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomised, Double-blind Phase III Trial to Investigate the Efficacy and Safety of BIBF 1120 in Combination With Carboplatin and Paclitaxel Compared to Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
Brief Summary: The trial will be performed to evaluate if BIBF 1120 in combination with paclitaxel and carboplatin is more effective than placebo in combination with paclitaxel and carboplatin in first-line treatment of patients with advanced ovarian cancer. Safety information about BIBF1120/paclitaxel/carboplatin will be obtained.


Options:
A: Arm Label: Olaparib 300mg tablets; Type: EXPERIMENTAL; Interventions: Drug: Olaparib 300mg tablets | Arm Label: Placebo tablets; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match olaparib 300mg | Intervention Type: DRUG; Name: Olaparib 300mg tablets; Assigned to Arm(s): Olaparib 300mg tablets | Intervention Type: DRUG; Name: Placebo to match olaparib 300mg; Assigned to Arm(s): Placebo tablets
B: Arm Label: BIBF 1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120, Drug: Paclitaxel, Drug: Carboplatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): BIBF 1120 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): BIBF 1120 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): BIBF 1120
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: brivanib | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: brivanib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Arm Label: Chemotherapy + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: liposomal doxorubicin; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: topotecan; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Controlled and Prospective Pilot Study on the Effects of Intensified Sodium Management on Hospitalization in Chronic Hemodialysis Patients.
Brief Summary: The primary aim of this study is to investigate whether intensive sodium management by dietary sodium restriction and by preventing positive sodium balance during dialysis can be successfully applied in chronic hemodialysis patients. Secondary aims are to test if sodium restriction has positive effects on the frequency of hospital admissions, blood pressure, fluid overload, quality of life and residual renal function.


Options:
A: Arm Label: Intervention SUBLIME; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention SUBLIME | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention SUBLIME; Assigned to Arm(s): Intervention SUBLIME
B: Arm Label: Sodium Reduction; Type: EXPERIMENTAL; Interventions: Behavioral: Sodium Reduction | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Sodium Reduction; Assigned to Arm(s): Sodium Reduction
C: Arm Label: intensive sodium management; Type: EXPERIMENTAL; Interventions: Other: intensive sodium management | Arm Label: standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: intensive sodium management; Assigned to Arm(s): intensive sodium management
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: BalanceWise-PD | Arm Label: B; Type: OTHER; Interventions: Behavioral: Attention control | Intervention Type: BEHAVIORAL; Name: BalanceWise-PD; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Attention control; Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Study of Azacitidine (Vidaza®) Combined to Epoetin Beta (NeoRecormon®) in IPSS Low-risk and Intermediate-1 MDS Patients, Resistant to ESA
Brief Summary: The study is aimed to treat low-risk MDS patients,who are dependent on red-blood cell transfusion due to disease-related anemia, and who have a proven resistance towards treatment with erythropoetin-stimulating agents (ESA). The study randomizes patients to receive a treatment with the demethylating agent 5-azacytidine alone or in combination with an ESA. The study thus evaluates, if efficacy of 5-azacytidine, notably on the red-blood cell transfusion-dependence is comparable/inferior to a combination treatment with azacitidine and an ESA (that is if 5-azacytidine can overcome the resistance towards ESA). Being a phase II study, the study assesses, duration of erythroid response, overall survival and time to progression as well as toxicity.


Options:
A: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azacitidine | Arm Label: Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azacitidine, Drug: Epoetin beta | Intervention Type: DRUG; Name: Azacitidine; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Epoetin beta; Assigned to Arm(s): Arm B
B: Arm Label: EPO plus sustained iron dextran; Type: EXPERIMENTAL; Interventions: Drug: Erythropoietins (EPO), Drug: Sustained iron dextran supplementation | Arm Label: EPO plus aggressive iron dextran; Type: EXPERIMENTAL; Interventions: Drug: Erythropoietins (EPO), Drug: Aggressive iron dextran supplementation | Arm Label: Double EPO; Type: ACTIVE_COMPARATOR; Interventions: Drug: Erythropoietins (EPO) | Intervention Type: DRUG; Name: Erythropoietins (EPO); Assigned to Arm(s): EPO plus aggressive iron dextran, EPO plus sustained iron dextran | Intervention Type: DRUG; Name: Aggressive iron dextran supplementation; Assigned to Arm(s): EPO plus aggressive iron dextran | Intervention Type: DRUG; Name: Erythropoietins (EPO); Assigned to Arm(s): Double EPO | Intervention Type: DRUG; Name: Sustained iron dextran supplementation; Assigned to Arm(s): EPO plus sustained iron dextran
C: Arm Label: Darbepoetin alfa 6.75 mcg/kg Q4W; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin Alfa | Arm Label: Placebo Q4W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin Alfa; Assigned to Arm(s): Darbepoetin alfa 6.75 mcg/kg Q4W | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Q4W
D: Arm Label: Intravenous iron; Type: EXPERIMENTAL; Interventions: Drug: Intravenous iron | Arm Label: Oral iron; Type: PLACEBO_COMPARATOR; Interventions: Drug: Intravenous iron | Intervention Type: DRUG; Name: Intravenous iron; Assigned to Arm(s): Intravenous iron, Oral iron

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Healthy Opportunities for Physical Activity and Nutrition (HOP'N) After-School Project
Brief Summary: This study presents evaluates the effectiveness of the Healthy Opportunities for Physical Activity(HOP'N) After-School Program on preventing obesity in children. The investigators hypothesized that normal and overweight/obese children attending after-school sites randomized to the control condition will increase in weight status to a greater extent compared to children at sites randomized to receive the HOP'N program. The investigators also hypothesized that after-school intervention HOP'N sites will increase in physical activity and healthful eating opportunities compared to control sites.


Options:
A: Arm Label: SCORES; Type: EXPERIMENTAL; Interventions: Behavioral: America SCORES, Bay Area | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: America SCORES, Bay Area; Assigned to Arm(s): SCORES
B: Intervention Type: BEHAVIORAL; Name: Beat Osteoporosis: Nourish and Exercise Skeletons (BONES) Project; Assigned to Arm(s): N/A
C: Arm Label: HOP'N After-School Program; Type: EXPERIMENTAL; Interventions: Behavioral: HOP'N After-school Program | Intervention Type: BEHAVIORAL; Name: HOP'N After-school Program; Assigned to Arm(s): HOP'N After-School Program
D: Arm Label: After school sports; Type: EXPERIMENTAL; Interventions: Behavioral: After school sports program | Arm Label: After school health education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: After school health education | Intervention Type: BEHAVIORAL; Name: After school sports program; Assigned to Arm(s): After school sports | Intervention Type: BEHAVIORAL; Name: After school health education; Assigned to Arm(s): After school health education

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Healthy Opportunities for Physical Activity and Nutrition (HOP'N) After-School Project
Brief Summary: This study presents evaluates the effectiveness of the Healthy Opportunities for Physical Activity(HOP'N) After-School Program on preventing obesity in children. The investigators hypothesized that normal and overweight/obese children attending after-school sites randomized to the control condition will increase in weight status to a greater extent compared to children at sites randomized to receive the HOP'N program. The investigators also hypothesized that after-school intervention HOP'N sites will increase in physical activity and healthful eating opportunities compared to control sites.


Options:
A: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Sleep hygiene counseling | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Sleep hygiene counseling; Assigned to Arm(s): Intervention group
B: Arm Label: HOP'N After-School Program; Type: EXPERIMENTAL; Interventions: Behavioral: HOP'N After-school Program | Intervention Type: BEHAVIORAL; Name: HOP'N After-school Program; Assigned to Arm(s): HOP'N After-School Program
C: Arm Label: Education Home Visits; Type: EXPERIMENTAL; Interventions: Other: Education Home Visits | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Education Home Visits; Assigned to Arm(s): Education Home Visits
D: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Vaasa Childhood Obesity Primary Prevention Study | Intervention Type: BEHAVIORAL; Name: Vaasa Childhood Obesity Primary Prevention Study; Assigned to Arm(s): Lifestyle counseling

Answer: B